The Efficacy and Safety of Sofosbuvir/Ledipasvir Therapy in Patients on Long-term Hemodialysis with Hepatitis C Virus Infection.
作者信息
Cavoli G Li, Schillaci O, Zagarrigo C, Servillo F, Li Cavoli T V, Palmeri M, Rotolo U
机构信息
Department of Nephrology-Dialysis, Civico and Di Cristina Hospital, Palermo, Italy.
出版信息
Indian J Nephrol. 2018 Mar-Apr;28(2):175-176. doi: 10.4103/ijn.IJN_35_17.
Abstract
摘要
相似文献
1
The Efficacy and Safety of Sofosbuvir/Ledipasvir Therapy in Patients on Long-term Hemodialysis with Hepatitis C Virus Infection.索磷布韦/来迪帕司韦治疗丙型肝炎病毒感染的长期血液透析患者的疗效和安全性
Indian J Nephrol. 2018 Mar-Apr;28(2):175-176. doi: 10.4103/ijn.IJN_35_17.
2
Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.在未经治疗和先前经治的日本基因 1 型丙型肝炎患者中，使用利巴韦林联合或不联合利巴韦林的雷迪帕韦和索非布韦固定剂量复方制剂治疗 12 周：一项开放标签、随机、3 期临床试验。
Lancet Infect Dis. 2015 Jun;15(6):645-53. doi: 10.1016/S1473-3099(15)70099-X. Epub 2015 Apr 8.
3
Ledipasvir/sofosbuvir without ribavirin is effective in the treatment of recurrent hepatitis C virus infection post-liver transplant.来迪派韦索磷布韦片联合利巴韦林治疗肝移植后复发的丙型肝炎病毒感染有效。
Hepatol Int. 2017 Sep;11(5):434-439. doi: 10.1007/s12072-016-9778-6. Epub 2017 Jan 12.
4
Ledipasvir and Sofosbuvir for untreated HCV genotype 1 infection in end stage renal disease patients: A prospective observational study.来迪派韦和索磷布韦用于治疗终末期肾病患者未经治疗的丙型肝炎病毒1型感染：一项前瞻性观察研究。
Hemodial Int. 2018 Apr;22(2):217-221. doi: 10.1111/hdi.12604. Epub 2017 Oct 3.
5
Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis.利巴韦林联合或不联合索磷布韦与达卡他韦治疗慢性丙型肝炎病毒感染和肝硬化患者的安全性和有效性
Clin Gastroenterol Hepatol. 2018 Nov;16(11):1811-1819.e4. doi: 10.1016/j.cgh.2017.12.037. Epub 2018 Jan 3.
6
Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients.来迪派韦/索磷布韦与达卡他韦/索磷布韦治疗丙型肝炎病毒4型慢性患者的疗效比较
Curr Drug Saf. 2020;15(1):53-60. doi: 10.2174/1574886314666191001151314.
7
Ledipasvir-sofosbuvir: interferon-/ribavirin-free regimen for chronic hepatitis C virus infection.来迪派韦-索磷布韦：用于慢性丙型肝炎病毒感染的无干扰素/利巴韦林治疗方案。
Ann Pharmacother. 2015 Mar;49(3):343-50. doi: 10.1177/1060028014563952. Epub 2014 Dec 16.
8
Safety and efficacy of ledipasvir/sofosbuvir on hepatitis C eradication in hepatitis C virus/human immunodeficiency virus co-infected patients.来迪派韦/索磷布韦治疗丙型肝炎病毒/人类免疫缺陷病毒合并感染患者丙肝根除的安全性和有效性
World J Hepatol. 2017 Oct 28;9(30):1190-1196. doi: 10.4254/wjh.v9.i30.1190.
9
The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection.来迪派韦索磷布韦治疗 12-17 岁 1 型丙型肝炎病毒感染青少年的安全性和有效性。
Hepatology. 2017 Aug;66(2):371-378. doi: 10.1002/hep.28995. Epub 2017 Jun 19.
10
Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study.索磷布韦联合利巴韦林和索磷布韦联合来迪派韦治疗基因型 1 或 3 丙型肝炎病毒合并严重肾功能损害患者：一项多中心、2b 期、非随机、开放标签研究。
Lancet Gastroenterol Hepatol. 2020 Oct;5(10):918-926. doi: 10.1016/S2468-1253(19)30417-0. Epub 2020 Jun 10.
引用本文的文献
1
Safety and Efficacy of Direct-acting Antiviral Therapies for Chronic HCV Infection in Hemodialysis Patients.直接作用抗病毒药物治疗血液透析患者慢性 HCV 感染的安全性和疗效。
In Vivo. 2022 Nov-Dec;36(6):2918-2922. doi: 10.21873/invivo.13033.
本文引用的文献
1
Corrigendum to 'EASL recommendations on treatment of hepatitis C: Final update of the series [J Hepatol 73 (2020) 1170-1218].《欧洲肝脏研究学会丙型肝炎治疗推荐：系列最终更新版》勘误 [《肝脏病学杂志》73卷（2020年）1170 - 1218页]
J Hepatol. 2023 Feb;78(2):452. doi: 10.1016/j.jhep.2022.10.006. Epub 2022 Dec 1.
2
Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment.肾功能损害患者丙型肝炎病毒感染的新疗法。
J Clin Transl Hepatol. 2016 Dec 28;4(4):320-327. doi: 10.14218/JCTH.2016.00032. Epub 2016 Dec 26.
3
Effectiveness of direct-acting antivirals in Hepatitis C virus infection in haemodialysis patients.直接作用抗病毒药物在血液透析患者丙型肝炎病毒感染中的疗效
Nefrologia. 2017 Mar-Apr;37(2):158-163. doi: 10.1016/j.nefro.2016.10.003. Epub 2016 Nov 30.
4
Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function.含索磷布韦方案在肾功能受损的丙型肝炎感染患者中的安全性和有效性。
Liver Int. 2016 Jun;36(6):807-16. doi: 10.1111/liv.13102. Epub 2016 Mar 24.
5
KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease.KDIGO慢性肾脏病丙型肝炎预防、诊断、评估及治疗临床实践指南。
Kidney Int Suppl. 2008 Apr(109):S1-99. doi: 10.1038/ki.2008.81.
Zotero 插件